NNC 55-0414

NNC 55-0414 is a small molecule drug developed by Novo Nordisk for the treatment of metabolic and endocrine diseases, with a primary focus on type 2 diabetes. It has been evaluated in at least one completed phase 1 clinical trial as an oral agent to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with type 2 diabetes. The specific molecular target and mechanism of action have not been publicly disclosed in available sources. Its development status is currently listed as pending or inactive for type 2 diabetes[1][3][4].

Other names

279215-43-96-chloro-N-(1-methylcyclopropyl)-1,1-dioxo-4H-thieno[3,2-e][1,2,4]thiadiazin-3-amine6-Chloro-3-((1-methylcyclopropyl)amino)-2H-thieno[3,2-e][1,2,4]thiadiazine 1,1-dioxide2H-Thieno(3,2-e)-1,2,4-thiadiazin-3-amine, 6-chloro-N-(1-methylcyclopropyl)-, 1,1-dioxide